Evaluation of inhibitory activity of few selected triazoles on xanthine oxidase – In silico studies

Abstract

Hyperuricemia, also called Gout is a medical term used for joints pain associated with increased levels of uric acid in
blood serum of a patient. The end product of purine metabolism in human body is uric acid. An enzyme called Xanthine
Oxidase (XO) is a catalyst for this purine metabolism. Inhibitor which reduces the activity of an enzyme is used as a
therapeutic agent to maintain the desired levels of uric acid in blood serum of patients. Such available inhibitors in the
market include Febuxostat and Allopurinol which are widely used by Rheumatologists. The search for new molecules
which can act as better inhibitor than the inhibitors presently available in the market is never ending. Eighteen various
triazole (5 newly designed) compounds have been identified and their inhibitory activity(in silico) is evaluated on Xanthine
Oxidase and it is found that all these triazoles show much better inhibitory activity on said enzyme, when compared to
Febuxostat and Allopurinol.